Cargando…
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
There is good evidence to suggest that dose intensity is important when considering the effectiveness of adjuvant chemotherapy in patients with breast cancer. However, the development of chemotherapy-induced febrile neutropenia can lead to reduction in dose intensity and other treatment modification...
Autores principales: | Kelly, S, Wheatley, D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752223/ https://www.ncbi.nlm.nih.gov/pubmed/19756005 http://dx.doi.org/10.1038/sj.bjc.6605269 |
Ejemplares similares
-
Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014) -
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010) -
Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer
por: Aapro, Matti S., et al.
Publicado: (2023) -
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010) -
Appropriateness of granulocyte colony-stimulating factor use in
patients receiving chemotherapy by febrile neutropenia risk
level
por: Baig, Hassam, et al.
Publicado: (2018)